Fidelity Disruptive Medicine ETF
FMED
Market cap $52.4M

23.80 USD

-0.38

1.57%

At close Jul 11, 4:00 PM EDT

1 day

-1.57%

5 days

-0.17%

1 month

-1.24%

3 months

4.66%

6 months

-5.71%

Year to date

-3.88%

1 year

-3.29%

5 years

-5.85%

10 years

-5.85%

0

Funds holding %

of 7,312 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0.29% more ownership

Funds ownership: 61.84% [Q4 2024] → 62.13% (+0.29%) [Q1 2025]

4% less capital invested

Capital invested by funds: $32.3M [Q4 2024] → $31.1M (-$1.23M) [Q1 2025]

25% less funds holding

Funds holding: 8 [Q4 2024] → 6 (-2) [Q1 2025]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for FMED.

See Analyst Rankings

Financial journalist opinion

Exploring Key Tailwinds for Fidelity's Disruptive ETFs

Fidelity Investment's suite of disruptive ETFs are designed to capture growth opportunities arising from groundbreaking innovation and transformative technologies.

Exploring Key Tailwinds for Fidelity's Disruptive ETFs

First Look At FMED: Poor Performance Merits A Strong Sell Rating

Fidelity Disruptive Medicine ETF invests in innovative healthcare companies, focusing on sectors like robotic surgery, genomics, and advanced diagnostics, aiming to disrupt traditional medical practices. The ETF employs a bottom-up stock picking approach, benchmarking against the MSCI ACWI Index and MSCI All Country World Healthcare Equal Weighted Index. Based on the results so far, this strategy has been a dud, earning this ETF another Strong Sell rating for this series of ETFs.

First Look At FMED: Poor Performance Merits A Strong Sell Rating

As Biotech Outlook Grows Healthier, Look to Disruptive ETF FMED

Could now be the time to invest in biotech? The space, which performed well in 2020 and 2021, dropped off in the interim amid high interest rates and slowing deal-making.

As Biotech Outlook Grows Healthier, Look to Disruptive ETF FMED

An Advisor's Guide to Fidelity's Disruptive ETF Suite

Thematic investing continues to garner attention at the midyear point on sustained artificial intelligence interest. For advisors and investors looking to diversify their thematic holdings, the Disruptive ETF suite from Fidelity offers strategies cutting across several sectors.

An Advisor's Guide to Fidelity's Disruptive ETF Suite

Eye Disruptive Medicine ETF FMED to Start 2024

Could healthcare innovation be one potent opportunity area to start 2024? Healthcare investing wasn't necessarily the best in 2023.

See News Rankings

Charts implemented using Lightweight Charts™